Staar Surgical's stock surged 15.64% in after-hours trading on Wednesday following the release of its first-quarter financial results, which significantly exceeded analyst expectations.

The intraocular lens maker reported a swing to profitability with Q1 earnings of $0.10 per diluted share, beating the consensus estimate of an $0.05 loss. Revenue more than doubled year-over-year to a record $93.5 million, well above the $78.7 million analysts had forecast. The company attributed the strong performance to a recovery in demand in China, normalization of distributor inventory, and the successful launch of its EVO+ ICL product in the region.

Gross margin improved to 73.6% from 65.8% a year earlier, driven by manufacturing efficiencies and lower costs. Management expressed confidence in consistent, profitable growth for 2026, with plans for its Swiss facility to supply all lenses shipped to China, thereby avoiding import tariffs.